ClinicalTrials.gov
ClinicalTrials.gov Menu

Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01541332
Recruitment Status : Unknown
Verified March 2016 by Oncotherapeutics.
Recruitment status was:  Active, not recruiting
First Posted : February 29, 2012
Last Update Posted : March 10, 2016
Sponsor:
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Oncotherapeutics

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2016
  Estimated Study Completion Date : December 2016